Associated Papers
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA et al.
Antimicrobial Agents and Chemotherapy, 2010
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
Croteau G et al.
Journal of Virology, 1997
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
Doyon L et al.
Journal of Virology, 1996
Select a paper to view details